

Change in number of shares and votes in SynAct Pharma AB

SynAct Pharma AB (the "Company") announces that the number of shares and votes has increased by 1,004,100 as a result of conversion of warrants, which was carried out in August 2025.

Today, the last trading day of the month, the total number of shares and votes in the Company amounts to 53,330,243. The conversion of 1 million warrants in August generated a total of 1,004,100 new shares, providing the company with SEK 17.7 million.

For further information, please contact:
Björn Westberg, CFO SynAct Pharma Tel: +46 733 940 953
Email: investor.relations@synactpharma.com

About SynAct Pharma AB

SynAct Pharma AB (publ) (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and anti-inflammatory activity in autoimmune and inflammatory diseases to help patients achieve immune balance and overcome their inflammation. For more information: www.synactpharma.com.

This information is information that SynAct Pharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2025-08-29 18:00 CEST.

Attachments

[Change in number of shares and votes in SynAct Pharma AB](#)